Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Cosmo Bio CoTSE:3386 -0.72%73 EV-to-EBIT is 6.71 as of Aug. 26, 2026, which is 35% below its 10-year median of 10.30. GuruFocus rates TSE:3386 with a GF Score™ of 73/100 and a GF Value™ of 円1,310.49 (Fairly Valued). The stock has 4 warning signs investors should review. Among 106 Medical Diagnostics & Research companies, Cosmo Bio Co ranks better than 86.79% on this metric.
The historical rank and industry rank for Cosmo Bio Co's EV-to-EBIT or its related term are showing as below:
TSE:3386'
s EV-to-EBIT Range Over the Past 10 Years
Min: 2.43 Med: 10.3 Max: 20.79
Current: 6.71
During the past 13 years, the highest EV-to-EBIT of Cosmo Bio Co was 20.79. The lowest was 2.43. And the median was 10.30.
TSE:3386's EV-to-EBIT is ranked better than 86.79% of 106
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.975
vs TSE:3386: 6.71
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Cosmo Bio Co's Enterprise Value for the quarter that ended in Jun. 2026 was 円3,540 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was 円542 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co EV-to-EBIT Related Terms
Cosmo Bio Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Cosmo Bio Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Cosmo Bio Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosmo Bio Co EV-to-EBIT vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Cosmo Bio Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Cosmo Bio Co's EV-to-EBIT falls into.
Cosmo Bio Co's current Enterprise Value is 円3,637 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Cosmo Bio Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was 円542 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosmo Bio Co (TSE:3386) has a EV-to-EBIT of 6.71 as of Aug. 26, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cosmo Bio Co and its competitors. This is 35% below median its historical median of 10.30. Over the past decade, Cosmo Bio Co's EV-to-EBIT has ranged from 2.43 to 20.79. According to the industry distribution chart, Cosmo Bio Co ranks #14 out of 106 companies in the Medical Diagnostics & Research industry, placing it in the top 13.2%.
Is Cosmo Bio Co's EV-to-EBIT too high?
Cosmo Bio Co's current EV-to-EBIT of 6.71 is 35% below median its 10-year median of 10.30. Over the past 10 years, this metric has ranged from a low of 2.43 to a high of 20.79. The Medical Diagnostics & Research industry median EV-to-EBIT is 22.98. Cosmo Bio Co's value of 6.71 is 70.8% below this industry median. Based on the distribution chart, Cosmo Bio Co ranks #14 out of 106 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Cosmo Bio Co has a GF Score™ of 73/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosmo Bio Co's EV-to-EBIT compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Cosmo Bio Co ranks #14 out of 106 companies for EV-to-EBIT. This places Cosmo Bio Co in the top 13% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 22.98. Cosmo Bio Co's value of 6.71 is 70.8% below this benchmark. Historically, Cosmo Bio Co's own EV-to-EBIT has ranged from 2.43 to 20.79 over the past decade. While the company's 10-year median is 10.30 vs. the industry median of 22.98, Cosmo Bio Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Diagnostics & Research company?
The median EV-to-EBIT among Medical Diagnostics & Research companies is 22.98, based on 106 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cosmo Bio Co's current EV-to-EBIT of 6.71 is 70.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Cosmo Bio Co and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-EBIT is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cosmo Bio Co's current EV-to-EBIT is 6.71, which is 35% below median its own 10-year median of 10.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosmo Bio Co stock overvalued right now?
Based on GuruFocus' analysis, Cosmo Bio Co (TSE:3386) is currently considered Fairly Valued. The stock's GF Value™ is 円1,310.49, compared to a current price of 円1,245.00 — trading 5% below its estimated fair value. The current EV-to-EBIT is 6.71, which is 35% below median its 10-year median of 10.30 and 70.8% below the Medical Diagnostics & Research industry median of 22.98. Cosmo Bio Co's overall GF Score™ is 73/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Cosmo Bio Co (TSE:3386), the current EV-to-EBIT is 6.71 as of Aug. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosmo Bio Co (TSE:3386) Overvalued in 2026?
Based on GuruFocus' analysis, Cosmo Bio Co stock appears to be undervalued.
The current stock price of 円1,245.00 is trading 5% below its estimated GF Value™ of 円1,310.49.
GuruFocus considers Cosmo Bio Co to be Fairly Valued.
Key valuation signals for TSE:3386:
EV-to-EBIT: 6.71 (35% below median its 10-year median of 10.30)
GF Value™: 円1,310.49 vs. price of 円1,245.00 (5% below fair value)
Industry Position: 70.8% below the Medical Diagnostics & Research median (#14 of 106)
No single metric tells the full story. See the TSE:3386 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosmo Bio Co Ltd is a diagnostic and research company based in Japan. The business of the company includes the purchase of reagents, instruments, and clinical test drugs for research in life science and domestic sales.
73GF Score
Get the complete analysis for TSE:3386
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3386 has been successfully added to your 
